No Data
China Resources Sanjiu Medical & Pharmaceutical (000999): Performance meets expectations with strong resilience for internal and external development.
In the first three quarters of 2024, the company achieved revenue of 19.74 billion yuan, a year-on-year increase of 6.08%; net income attributable to shareholders was 2.96 billion yuan, a year-on-year increase of 23.19%; non-net profit attributable to shareholders was 2.752 billion yuan, a year-on-year increase of 19.
AVIC Securities: Pharmaceutical industry performance under pressure in the third quarter, total market value of heavyweight in fund holdings increased.
The demand for blood sector in biological products remains high, with vaccines facing sales pressure due to factors such as previous market consumption; active pharmaceutical ingredients are entering the tail end of downstream inventory, showing an improvement in demand, and future performance is expected to gradually improve.
China Resources Sanjiu Medical & Pharmaceutical (000999): Short-term profit margins are under some pressure, long-term traditional Chinese medicine industry chain layout continues to advance.
In the third quarter of 2024, the single-quarter revenue slightly increased, with the non-net profit attributable to the parent company under some pressure. In the first three quarters of 2024, the company achieved revenue of 19.74 billion yuan, a year-on-year increase of 6.08%; achieving net profit attributable to the shareholders of the listed company
China Resources Sanjiu Medical & Pharmaceutical (000999) Third Quarter Report Review 2024: CHC business steadily growing, global strategy actively advancing.
Event: China Resources Sanjiu Medical & Pharmaceutical released the third quarter report for 2024, achieving revenue of 19.74 billion yuan in the first three quarters (+6.08% year-on-year), net income attributable to parent company of 2.96 billion yuan (+23.19% year-on-year), and non-net profit of 2
Express News | 215 companies distributed dividends in the third quarter, with a total amount exceeding 29.1 billion yuan.
CR Sanjiu's Nine-Month Profit Increases
No Data
No Data